Fenimore Asset Management Inc. boosted its holdings in Waters Co. (NYSE:WAT) by 10.8% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 319,282 shares of the medical instruments supplier’s stock after purchasing an additional 31,149 shares during the quarter. Waters makes up 2.4% of Fenimore Asset Management Inc.’s portfolio, making the stock its 13th largest position. Fenimore Asset Management Inc.’s holdings in Waters were worth $60,233,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the business. Caledonia Investments PLC boosted its holdings in shares of Waters by 41.1% during the 4th quarter. Caledonia Investments PLC now owns 127,000 shares of the medical instruments supplier’s stock valued at $23,959,000 after purchasing an additional 37,000 shares during the last quarter. Copper Rock Capital Partners LLC boosted its holdings in shares of Waters by 84.2% during the 4th quarter. Copper Rock Capital Partners LLC now owns 80,713 shares of the medical instruments supplier’s stock valued at $14,913,000 after purchasing an additional 36,904 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Waters by 2,038.2% during the 3rd quarter. Marshall Wace LLP now owns 26,343 shares of the medical instruments supplier’s stock valued at $5,128,000 after purchasing an additional 25,111 shares during the last quarter. Great Lakes Advisors LLC bought a new position in shares of Waters during the 3rd quarter valued at about $465,000. Finally, Morgan Stanley boosted its holdings in shares of Waters by 188.1% during the 3rd quarter. Morgan Stanley now owns 527,562 shares of the medical instruments supplier’s stock valued at $102,707,000 after purchasing an additional 344,432 shares during the last quarter. Institutional investors and hedge funds own 92.22% of the company’s stock.
Several research analysts have commented on WAT shares. Leerink Swann downgraded shares of Waters from an “outperform” rating to a “market perform” rating in a report on Monday, October 8th. Morgan Stanley increased their price objective on shares of Waters from $204.00 to $211.00 and gave the company an “equal weight” rating in a report on Wednesday, October 10th. JPMorgan Chase & Co. dropped their price objective on shares of Waters from $200.00 to $185.00 and set a “neutral” rating for the company in a report on Wednesday, October 24th. Barclays dropped their price objective on shares of Waters from $200.00 to $190.00 and set an “equal weight” rating for the company in a report on Wednesday, October 24th. Finally, UBS Group dropped their price objective on shares of Waters from $210.00 to $200.00 and set a “neutral” rating for the company in a report on Wednesday, October 24th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $201.92.
In other Waters news, SVP Michael C. Harrington sold 1,131 shares of the firm’s stock in a transaction dated Friday, December 14th. The shares were sold at an average price of $189.53, for a total value of $214,358.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas P. Salice sold 3,500 shares of the firm’s stock in a transaction dated Wednesday, October 31st. The stock was sold at an average price of $192.00, for a total transaction of $672,000.00. Following the completion of the sale, the director now directly owns 20,911 shares of the company’s stock, valued at approximately $4,014,912. The disclosure for this sale can be found here. In the last three months, insiders sold 37,159 shares of company stock valued at $7,127,100. 0.98% of the stock is owned by insiders.
Shares of NYSE:WAT traded up $0.79 during trading on Friday, reaching $197.76. The company’s stock had a trading volume of 7,912 shares, compared to its average volume of 523,266. The company has a current ratio of 6.63, a quick ratio of 5.93 and a debt-to-equity ratio of 0.61. Waters Co. has a 12 month low of $167.93 and a 12 month high of $220.20. The company has a market cap of $14.77 billion, a price-to-earnings ratio of 26.45, a PEG ratio of 1.81 and a beta of 0.92.
Waters (NYSE:WAT) last announced its quarterly earnings data on Tuesday, October 23rd. The medical instruments supplier reported $1.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.90 by $0.02. The business had revenue of $578.02 million during the quarter, compared to the consensus estimate of $587.43 million. Waters had a net margin of 2.32% and a return on equity of 30.68%. The firm’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.77 earnings per share. As a group, equities analysts forecast that Waters Co. will post 8.07 EPS for the current year.
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Featured Article: What is a Roth IRA?
Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Co. (NYSE:WAT).